# South Korea obesity and diabetes medication regulation

> Developing situation record from CLSTR: https://clstr.news/situations/south-korea-obesity-and-diabetes-medication-regulation
> Updated: 2026-11-18T02:09:45.000Z. Sources: 20. Developments: 4.

In late October 2026, the South Korean Ministry of Food and Drug Safety expanded the approved indications for Mounjaro (tirzepatide). The medication is now approved for adult type 2 diabetes patients with established cardiovascular disease to reduce the risk of major adverse cardiovascular events, as well as for pediatric patients aged 10 and older to improve glycemic control. By mid-November 2026, South Korean authorities further relaxed customs policies regarding obesity treatments. Effective November 12, 2026, travelers are permitted to personally carry medications such as Wegovy and Mounjaro that were legally prescribed and purchased abroad for personal use, up to a three-month supply. This relaxation has intensified the “Sushijaro” trend, where South Koreans travel to Japan to purchase Mounjaro because it costs approximately one-fourth of the price in South Korea. This trend is fueled by a weak Japanese yen and the availability of Japanese telemedicine services that offer delivery to hotels. Digital tools, including apps that compare Japanese hospital prices and locations, have emerged to facilitate these trips. In response to concerns over illegal smuggling and unregulated prescription tourism, the Ministry of Food and Drug Safety established a special task force to combat the illegal distribution of GLP-1 class obesity treatments. The task force is monitoring social media, blogs, and second-hand marketplaces to identify illegal advertisements, brokerage, and peer-to-peer sales. Authorities emphasized that while importing medication for personal use is permitted, reselling these drugs or giving them away for free within South Korea violates the Pharmaceutical Affairs Act. Violators face up to five years in prison or fines of up to 50 million won.

## Timeline

### 2026-11-18: South Korea establishes task force to crack down on illegal obesity drug sales

South Korea has formed a special task force to crack down on the illegal resale and online distribution of obesity drugs like Wegovy and Mounjaro following increased overseas purchasing.

6 sources. https://clstr.news/cluster/south-korean-government-targets-illegal-resale-of-obesity-drugs

### 2026-11-15: South Koreans travel to Japan for cheaper obesity drugs

South Koreans are traveling to Japan to purchase obesity drugs like Mounjaro, driven by lower prices, a weak yen, and new regulations allowing the import of up to three months of prescribed overseas medicine.

3 sources. https://clstr.news/cluster/south-koreans-travel-to-japan-for-cheaper-obesity-drugs

### 2026-11-11: South Korea eases import restrictions on obesity drugs

South Korea now allows travelers to carry up to a three-month supply of legally prescribed obesity drugs like Wegovy and Mounjaro, following a policy change to ease customs restrictions.

15 sources. https://clstr.news/cluster/south-korea-permits-personal-import-of-wegovy-and-mounjaro

### 2026-10-26: Mounjaro receives expanded approval in South Korea for cardiovascular risk reduction

Mounjaro has received expanded approval in South Korea to reduce cardiovascular risks in adults with type 2 diabetes and to assist glycemic control in children aged 10 and older.

2 sources. https://clstr.news/cluster/mounjaro-receives-expanded-approval-in-south-korea-for-cardiovascular-risk-reduction

---
Cite as: South Korea obesity and diabetes medication regulation. CLSTR, https://clstr.news/situations/south-korea-obesity-and-diabetes-medication-regulation
